Breaking Finance News

A statement released earlier today by Joh. Berenberg Gossler & Co. KG about STRATEC Biomedical (ETR:SBS) bumps the target price to 53.00EUR

Having a price of 52.61EUR, STRATEC Biomedical (ETR:SBS) traded 0.74% higher on the day. With the last close up 19.18% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. STRATEC Biomedical has recorded a 50-day average of 9.13EUR and a two hundred day average of 8.01EUR. Volume of trade was down over the average, with 914,891 shares of SBS changing hands under the typical 2,135,280

Stating as potential upside of 0.01%, Joh. Berenberg Gossler & Co. KG upped the price target of STRATEC Biomedical (ETR:SBS) to 53.00EUR

On 09/22/2016, Joh. Berenberg Gossler & Co. KG released a statement on STRATEC Biomedical (ETR:SBS) upped the target price from 0.00EUR to 53.00EUR that suggested an upside of 0.01%.

Performance Chart

STRATEC Biomedical (ETR:SBS)

With a total market value of 0 EUR, STRATEC Biomedical has price-earnings ratio of 16.55 with a one year low of 3.46EUR and a one year high of 9.83EUR .

A total of 3 firms have issued a ratings update on the company. zero analysts rating the company a strong buy, 0 firms rating the stock a buy, 0 brokers rating the stock a hold, zero brokerages rating the stock a underperform, and finally zero firms rating the stock a sell with a consensus target price of 28.48EUR.

Brief Synopsis About STRATEC Biomedical (ETR:SBS)

STRATEC Biomedical AG (STRATEC) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC's partners market Company's products to pharmaceutical laboratories, blood banks and research institutes throughout the world. STRATEC Group operats through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *